FRA
EGRX
Front Row Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-40
| Closed | -$149 | – | 511 |
|
|
2024
Q3 | $149 | Hold |
40
| – | – | ﹤0.01% | 486 |
|
|
2024
Q2 | $224 | Hold |
40
| – | – | ﹤0.01% | 919 |
|
|
2024
Q1 | $210 | Hold |
40
| – | – | ﹤0.01% | 906 |
|
|
2023
Q4 | $209 | Hold |
40
| – | – | ﹤0.01% | 455 |
|
|
2023
Q3 | $631 | Hold |
40
| – | – | ﹤0.01% | 880 |
|
|
2023
Q2 | $1K | Hold |
40
| – | – | ﹤0.01% | 877 |
|
|
2023
Q1 | $1K | Buy |
+40
| New | +$1K | ﹤0.01% | 897 |
|
|
2022
Q4 | – | Sell |
-40
| Closed | -$1K | – | 956 |
|
|
2022
Q3 | $1K | Hold |
40
| – | – | ﹤0.01% | 911 |
|
|
2022
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 856 |
|
|
2022
Q1 | $2K | Hold |
40
| – | – | ﹤0.01% | 884 |
|
|
2021
Q4 | $2K | Hold |
40
| – | – | ﹤0.01% | 898 |
|
|
2021
Q3 | $2K | Hold |
40
| – | – | ﹤0.01% | 892 |
|
|
2021
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 895 |
|
|
2021
Q1 | $2K | Hold |
40
| – | – | ﹤0.01% | 891 |
|
|
2020
Q4 | $2K | Hold |
40
| – | – | ﹤0.01% | 853 |
|
|
2020
Q3 | $2K | Hold |
40
| – | – | ﹤0.01% | 851 |
|
|
2020
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 889 |
|
|
2020
Q1 | $2K | Hold |
40
| – | – | ﹤0.01% | 863 |
|
|
2019
Q4 | $2K | Hold |
40
| – | – | ﹤0.01% | 822 |
|
|
2019
Q3 | $2K | Hold |
40
| – | – | ﹤0.01% | 825 |
|
|
2019
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 886 |
|
|
2019
Q1 | $2K | Buy |
+40
| New | +$2K | ﹤0.01% | 884 |
|